Neurology News

A clinical stage biotech company has been awarded a grant for $873,000 by The Michael J. Fox Foundation for Parkinson’s Research to help assess sortilin inhibition in Parkinson’s disease.

The FDA has granted breakthrough therapy designation to PF614-MPAR, a “next-generation opioid” designed to limit oral overdose potential, according to a press release from its manufacturer.

Researchers at Sylvester Comprehensive Cancer Center at University of Miami devised an MRI-guided radiation therapy technique using machine learning that may allow for real-time monitoring of glioblastoma treatment response.

A biotechnology company has announced a partnership with a precision biomedicine firm to advance the use of electroencephalogram biomarkers across its clinical pipeline in neuropsychiatry and cognition.

A plasma phosphorylated-tau217 assay demonstrated a high degree of accuracy in identifying biomarkers consistent with Alzheimer’s disease-related pathology, according to research from JAMA Neurology.

Inflammasome Therapeutics announced that the first patient has been dosed in its phase 1 study of K8, a novel dual inflammasome inhibitor for treatment of diabetic macular edema.

For older adults with acute ischemic stroke, IV administration of an allogeneic cell therapy within 18 to 36 hours of onset was found to be safe but did not improve short-term outcomes, researchers reported in JAMA Neurology.

A Houston-based neurohealth company has received a patent for its non-invasive, frequency-based deep brain stimulation device to address a range of psychiatric and neurologic conditions.

Health Canada has approved Uplizna as a monotherapy for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.

In a cohort of older adults who smoked cannabis, impaired driving and elevated blood THC levels were significant 30 minutes after ingestion, according to research from JAMA Network Open.